Based on the critical requirement for HIF2α to drive the formation and growth of ccRCC, elegant work led to the development of HIF2α antagonists that disrupt ARNT-HIF2α heterodimers by interacting with a surface pocket in the PAS-B domain of HIF2α 26. Here, EPAS1 is linked to nonpapillary renal cell carcinoma.